Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).

Trial Details

NCT ID
NCT07783100
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Xiamen University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • venetoclax, chidamide, and chiglitazar sodium (VCC)
Locations (sample)
  • Xiamen, Fujian, China|24.47979,118.08187

Key Eligibility Criteria

  • Histologically confirmed acute myeloid leukemia (AML) with relapsed or refractory disease, including:
  • Refractory AML, defined as failure to achieve remission after at least one prior treatment;
  • Relapsed AML, defined as ≥5% blasts in the bone marrow after a previous remission;
  • AML arising from myelodysplastic syndrome (including CMML) or myeloproliferative neoplasms (secondary AML or therapy-related AML \[t-AML\]) is also…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →